<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00241618</url>
  </required_header>
  <id_info>
    <org_study_id>994058402</org_study_id>
    <secondary_id>AI054887</secondary_id>
    <secondary_id>AI41563</secondary_id>
    <secondary_id>Fulbright</secondary_id>
    <secondary_id>TEMPUS</secondary_id>
    <secondary_id>ISID</secondary_id>
    <nct_id>NCT00241618</nct_id>
  </id_info>
  <brief_title>Timing and Duration of Acute Hepatitis C Treatment</brief_title>
  <official_title>Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alexander von Humboldt Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fulbright</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tempus Labs</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>International Society for Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ain Shams University</source>
  <brief_summary>
    <textblock>
      Spontaneous resolution of acute hepatitis C infection cannot be predicted and the majority of&#xD;
      cases persist and become chronic. This randomized trial assesses the efficacy and safety of&#xD;
      peginterferon alfa-2b. The investigators hypothesize that therapy strategies could prevent&#xD;
      the development of chronic hepatitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With nearly 4 million people in the United States, and an estimated 170-200 million people&#xD;
      worldwide, the hepatitis C virus (HCV) represents a clear and significant public health&#xD;
      issue. Unfortunately, for most people infected with HCV (70%-85%) spontaneous resolution is&#xD;
      uncommon and 60% to 80% of patients with acute hepatitis C infection develop chronic&#xD;
      hepatitis. This randomized trial focuses on defining the effect of treatment of acute HCV on&#xD;
      prevention of chronic hepatitis in addition to optimization of the treatment regimen, onset&#xD;
      and the length of peginterferon alpha therapy in acute hepatitis C infections. This&#xD;
      randomized, multi-center prospective study assesses the efficacy of peginterferon in acute&#xD;
      hepatitis. We will also compare differences in sustained viral response rates in patients&#xD;
      with acute hepatitis C starting treatment at 8, 12, or 24 weeks. We will also compare the&#xD;
      efficacy of 8, 12 or 24 weeks therapy with PEG-IFN-alpha. All eligible patients are enrolled&#xD;
      and screened for an initial observation period starting from the time of their first positive&#xD;
      HCV-RNA-PCR, during which bi-weekly serum ALT and HCV-RNA subjects were performed. Patients&#xD;
      who did not resolve spontaneously (loss of HCV-RNA without treatment) by the end of the&#xD;
      observation period were randomly assigned to receive PEG-IFN-alpha at the assigned onset&#xD;
      and/or duration. Patients who do not consent to therapy at enrollment are included as a&#xD;
      non-randomized comparison group. All subjects with SVR were followed for 48 weeks after the&#xD;
      follow-up at 24 weeks when SVR was determined.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date>January 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained viral response rate in treatment group versus control</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of treatment virologic response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early virologic response at week 4</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <enrollment>180</enrollment>
  <condition>Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated interferon alpha 2</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-50 years, with or without symptoms&#xD;
&#xD;
          -  Diagnosis of acute hepatitis C: elevated serum alanine aminotransferase (ALT) &gt; 10&#xD;
             times the upper limit of normal (ULN)&#xD;
&#xD;
          -  Seroconversion from negative to positive anti-HCV antibody status (third-generation&#xD;
             enzyme-linked immunosorbent assay)&#xD;
&#xD;
          -  Conversion from negative to positive polymerase chain reaction (PCR) for HCV-RNA,&#xD;
             ruling out other causes of hepatitis by history and appropriate serologic and&#xD;
             virologic studies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated liver disease&#xD;
&#xD;
          -  Coinfection with human immunodeficiency virus (HIV) or Schistosoma mansoni&#xD;
&#xD;
          -  Marked anemia (hemoglobin level ≤ 120 g/L in women and ≤ 130 g/L in men)&#xD;
&#xD;
          -  Neutropenia (&lt; 1,500/mm3)&#xD;
&#xD;
          -  Thrombocytopenia (&lt; 90,000/mm3)&#xD;
&#xD;
          -  A creatinine concentration &gt; 1.5 times ULN&#xD;
&#xD;
          -  Serum alpha-fetoprotein &gt; 25 ng/ml&#xD;
&#xD;
          -  An organ transplant&#xD;
&#xD;
          -  Neoplastic disease&#xD;
&#xD;
          -  Severe cardiac or pulmonary disease&#xD;
&#xD;
          -  Unstable thyroid dysfunction&#xD;
&#xD;
          -  A psychiatric disorder&#xD;
&#xD;
          -  Seizure disorder&#xD;
&#xD;
          -  Severe retinopathy&#xD;
&#xD;
          -  A current pregnancy or were breast feeding or unwillingness to practice contraception&#xD;
&#xD;
          -  Therapy with immunomodulatory agents within the last 6 months&#xD;
&#xD;
          -  Alcohol or drug dependence within 1 year of study entry.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alaa Ismail, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sanaa M Kamal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ain Shams University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nezam H Afdhal, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harvard Medical School (HMS and HSDM)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Manal El Sayed, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASU</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASU</name>
      <address>
        <city>Cairo</city>
        <zip>03316</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASU Specialized Hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11351</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shebin Liver Center</name>
      <address>
        <city>Cairo</city>
        <zip>11351</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Kamal SM, Ismail A, Graham CS, He Q, Rasenack JW, Peters T, Tawil AA, Fehr JJ, Khalifa Kel S, Madwar MM, Koziel MJ. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology. 2004 Jun;39(6):1721-31.</citation>
    <PMID>15185314</PMID>
  </reference>
  <reference>
    <citation>Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, Schraut WW, Schirren CA, Waechtler M, Backmund M, Pape GR. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003 Jul;125(1):80-8.</citation>
    <PMID>12851873</PMID>
  </reference>
  <reference>
    <citation>Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, Ishibashi H, Kashiwagi S. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology. 2004 May;39(5):1213-9.</citation>
    <PMID>15122749</PMID>
  </reference>
  <reference>
    <citation>Kamal SM, Rasenack JW, Bianchi L, Al Tawil A, El Sayed Khalifa K, Peter T, Mansour H, Ezzat W, Koziel M. Acute hepatitis C without and with schistosomiasis: correlation with hepatitis C-specific CD4(+) T-cell and cytokine response. Gastroenterology. 2001 Sep;121(3):646-56.</citation>
    <PMID>11522749</PMID>
  </reference>
  <reference>
    <citation>Santantonio T, Sinisi E, Guastadisegni A, Casalino C, Mazzola M, Gentile A, Leandro G, Pastore G. Natural course of acute hepatitis C: a long-term prospective study. Dig Liver Dis. 2003 Feb;35(2):104-13.</citation>
    <PMID>12747629</PMID>
  </reference>
  <reference>
    <citation>Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology. 2004 Jul;40(1):98-107.</citation>
    <PMID>15239091</PMID>
  </reference>
  <reference>
    <citation>Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA, Saleh WA, Ismail A, Aziz AA, Madwar MA. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun;54(6):858-66.</citation>
    <PMID>15888797</PMID>
  </reference>
  <reference>
    <citation>Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, Pastore G, Dietrich M, Trautwein C, Manns MP; German Acute Hepatitis C Therapy Group. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001 Nov 15;345(20):1452-7.</citation>
    <PMID>11794193</PMID>
  </reference>
  <reference>
    <citation>Larghi A, Zuin M, Crosignani A, Ribero ML, Pipia C, Battezzati PM, Binelli G, Donato F, Zanetti AR, Podda M, Tagger A. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002 Oct;36(4 Pt 1):993-1000.</citation>
    <PMID>12297849</PMID>
  </reference>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>October 18, 2005</study_first_submitted>
  <study_first_submitted_qc>October 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2006</last_update_posted>
  <keyword>Clinical trial</keyword>
  <keyword>Randomized</keyword>
  <keyword>Treatment</keyword>
  <keyword>Prospective</keyword>
  <keyword>Parallel Assignment</keyword>
  <keyword>Efficacy Safety Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

